It is, however, noteworthy that two patents have been granted for peptide derivatives of amylin that can prevent amylin aggregation and amylin-mediated cytotoxicity and which have been suggested as potential therapeutic agents of type II diabetes [143, 144]. This evidence concerns the gene IAPP and type 2 diabetes mellitus.